Cleared Traditional

K883960 - GIPHY MONITOR (FDA 510(k) Clearance)

Class I Gastroenterology & Urology device.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 1989
Decision
379d
Days
Class 1
Risk

K883960 is an FDA 510(k) clearance for the GIPHY MONITOR. Classified as Electrode, Ph, Stomach (product code FFT), Class I - General Controls.

Submitted by Vascular Technology Incorporated (Chelmsford, US). The FDA issued a Cleared decision on October 4, 1989 after a review of 379 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Gastroenterology & Urology FDA review panel, regulated under 21 CFR 876.1400 - the FDA gastroenterology and urology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Gastroenterology & Urology review framework, consistent with the majority of Class II 510(k) submissions.

View all Vascular Technology Incorporated devices

Submission Details

510(k) Number K883960 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 20, 1988
Decision Date October 04, 1989
Days to Decision 379 days
Submission Type Traditional
Review Panel Gastroenterology & Urology (GU)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
249d slower than avg
Panel avg: 130d · This submission: 379d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code FFT Electrode, Ph, Stomach
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 876.1400
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.